Nymox Pharmaceutical Corporation news

   Watch this stock
Showing stories 1 - 10 of about 79   

Articles published

NYMX 1.53 +0.01 (0.66%)
price chart
Is Nymox a Fluke or Is It Back?
Nymox Pharmaceutical Corp. (NASDAQ: NYMX) has been around for a long time, but within the past five years the stock has literally fallen off a cliff.
Nymox Pharmaceutical Corporation (NASDAQ:NYMX) To Take Up Phase 3 BPH ...  USMarketsDaily (blog)
Class Action Lawsuit Filed Against Nymox Pharmaceutical Corporation and Paul ...
PHILADELPHIA, Nov. 25, 2014 (GLOBE NEWSWIRE) -- Law Offices Bernard M. Gross, P.C. filed a class action lawsuit in the United States District Court, District of New Jersey, 14-cv-07331, on behalf of purchasers of NYMOX common stock between January ...
Related articles »  
Nymox Pharmaceutical Corporation: Nymox Reports First Quarter 2015 ...
HASBROUCK HEIGHTS, NJ (May 15, 2015) Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced today its financial results for the first quarter of 2015 prepared in accordance with International Financial Reporting Standards.
Here's Why Nymox Nosedived Yesterday
Nymox Pharmaceutical Corporation (NYMX) was one of the biggest losers in the biotech sector yesterday, as its stock plunged almost 82% on news that the company's key drug candidate was unsuccessful in two late-stage trials.
Nymox Pharma (NYMX) Phase 3 Studies of NX-1207 Fail to Meet Primary ...  StreetInsider.com (subscription)
Nymox NX-1207 BPH Pivotal Phase 3 U.S. Studies NX02-0017 and NX02-0018 ...  GlobeNewswire (press release)
Related articles »  
Cohen, Placitella & Roth, PC Investigating Nymox Pharmaceutical Corporation ...
26, 2014 /PRNewswire/ -- Cohen, Placitella & Roth, PC is investigating potential claims on behalf of investors who purchased Nymox Pharmaceutical Corporation ("Nymox" or "Company") NYMX, -5.26% during the period from January 31, 2011 through ...
Related articles »  
Is Nymox Pharmaceutical Corp. (NASDAQ:NYMX)Back in Action?
One company that has been in the market for a pretty long time now thus making us accustomed to it is Nymox Pharmaceutical Corp. (NASDAQ:NYMX). However, in the last five years, Nymox Pharmaceutical Corp. (NASDAQ:NYMX)'s stock seems to have ...
Yesterday's Sizzling Gainers - Nymox Pharmaceutical Corporation, (NASDAQ ...
Yesterday, Nymox Pharmaceutical Corporation, declared long-term clinical trial results from the Company's NX-1207 Phase 2 prostate cancer study NX03-0040.
Nymox Pharmaceutical Corp. (NYMX) Is Spiking Higher On Study Results
Nymox Pharmaceutical Corp. (NYMX: Quote) just announced that results from its Phase 2 prostate cancer study demonstrated statistically significant better outcomes at up to 2.8 years for NX-1207 treated patients compared to controls.
Nymox Announces New Prostate Cancer Clinical Trial Results  GlobeNewswire (press release)
Mid-Day Changers: Nymox Pharmaceutical Corporation (NYMX), Paramount ...  WallStreet Scope
Rosen Law Firm Reminds Nymox Pharmaceutical Corporation Investors of ...
NEW YORK, Jan. 12, 2015 (GLOBE NEWSWIRE) -- The Rosen Law Firm reminds purchasers of Nymox Pharmaceutical Corporation common stock (Nasdaq:NYMX) during the period from January 31, 2011 through November 2, 2014, of the important January ...
Productive Stocks To Watch List: Kornit Digital, (NASDAQ:KRNT), Nymox ...
On the other hand, Nymox Pharmaceutical Corporation (NYMX), is undertaking further analyses of its pivotal U.S. Phase 3 studies of NX-1207 for prostate enlargement (BPH).